Skip to content

AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020
12.83 -0.32 -2.43%
Live - 5344 symbols - heartbeat 539s ago · 2026-10-08 08:30
Pre-market 12.60 -1.79%
After-hours 12.85 +0.16%
Overnight 12.81 -0.16%
Market cap
4.16B
P/B
4.64
EPS
-0.49
Reader sentiment Are you bullish or bearish on ABCL?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/8/6
  • Rating change
    Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $9
    Market Newswire · 2026/8/6
  • Rating change
    Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $12
    Market Newswire · 2026/5/22
  • J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17
    Market Newswire · 2026/9/29
  • Rating change
    JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/8/11
  • Rating change
    BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7
    Market Newswire · 2026/6/18
  • Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/9/2
  • Rating change
    Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $8
    Market Newswire · 2026/5/12
  • Rating change
    BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/8/18
  • Rating change
    Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
    Market Newswire · 2026/8/10
  • Rating change
    Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/7
  • Rating change
    Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $12
    Market Newswire · 2026/7/31
  • Rating change
    JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/7/30
  • Rating change
    Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/7/17
  • Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13
    Market Newswire · 2026/9/24
  • JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/9/28
  • Rating change
    TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
    Market Newswire · 2026/8/6
  • Rating change
    BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/8/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
    TipRanks · 2026/7/16
  • Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $30
    Market Newswire · 2026/8/12

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:30:15 · For reference only, not investment advice and not tailored to your situation.